We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+16.05%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.4B
AUM Growth
-$622M
Cap. Flow
-$2.95B
Cap. Flow %
-25.85%
Top 10 Hldgs %
75.13%
Holding
138
New
10
Increased
24
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$1.13B
2
ABBV icon
AbbVie
ABBV
+$938M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$82.3M
4
ATYR
aTyr Pharma
ATYR
+$51.8M
5
DYAX
DYAX CORPORATION
DYAX
+$50.5M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$2.31B
2
GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
+$1.14B
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$38M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$14.5M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 72.4%
2 Technology 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.5B
$1.55B 13.59%
14,865,559
+20,000
+0.1% +$2.07M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$1.49B 13.11%
30,870,262
+1,993,550
+7% +$82.3M
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$1.18B 10.37%
+6,542,599
New +$1.13B
ABBV icon
4
AbbVie
ABBV
$472B
$966M 8.47%
+14,373,538
New +$938M
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.43B
$858M 7.52%
20,481,442
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$12B
$560M 4.91%
4,095,247
-105,209
-3% -$13M
GHDX
7
DELISTED
Genomic Health, Inc.
GHDX
$380M 3.33%
13,657,598
+656
+0% +$18.5K
ANAC
8
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$281M 2.46%
3,625,498
-579,204
-14% -$38M
DYAX
9
DELISTED
DYAX CORPORATION
DYAX
$210M 1.84%
7,926,630
+1,905,145
+32% +$50.5M
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.43B
$173M 1.52%
11,577,299
+1,099,095
+10% +$12.5M
NVTA
11
DELISTED
Invitae Corporation
NVTA
$97.5M 0.86%
6,554,967
– –
BLCM
12
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$89.1M 0.78%
419,059
– –
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$88.3M 0.77%
2,805,074
– –
HRTX icon
14
Heron Therapeutics
HRTX
$91.6M
$87.5M 0.77%
2,807,784
+200,000
+8% +$3.76M
ONCE
15
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$76.1M 0.67%
1,262,382
-65,069
-5% -$4.3M
CERS icon
16
Cerus
CERS
$577M
$70.3M 0.62%
13,553,275
– –
XOMA
17
DELISTED
Xoma
XOMA
$57M 0.5%
734,176
-1,255
-0.2% -$90.4K
DBVT
18
DBV Technologies
DBVT
$800M
$55.5M 0.49%
186,202
+34,279
+23% +$8.86M
ARAV
19
DELISTED
Aravive, Inc. Common Stock
ARAV
$52.3M 0.46%
572,764
+76,531
+15% +$7.75M
ALDR
20
DELISTED
Alder Biopharmaceuticals
ALDR
$47.2M 0.41%
891,688
+12,107
+1% +$440K
HALO icon
21
Halozyme
HALO
$9.88B
$43.6M 0.38%
1,931,057
-317,095
-14% -$5.57M
ATYR
22
aTyr Pharma
ATYR
$47.3M
$43.2M 0.38%
+166,795
New +$51.8M
XNPT
23
DELISTED
XENOPORT, INC.
XNPT
$39.9M 0.35%
6,508,622
– –
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
$39.5M 0.35%
5,482,505
-176,250
-3% -$1.3M
INSM icon
25
Insmed
INSM
$22.7B
$38.7M 0.34%
1,583,490
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Baker Bros. Advisors held 138 positions worth $11.4B, down 5.2% from $12B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Baker Bros. Advisors withdrew a net $2.95B in Q2 2015, closing 12 positions and reducing 17 holdings. Its most notable exit was PHARMACYCLICS INC, an estimated $2.31B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 40% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Alexion Pharmaceuticals worth $1.18B.

  • Baker Bros. Advisors's largest Q2 2015 buy was Alexion Pharmaceuticals: 6,542,599 shares worth $1.18B.
  • Baker Bros. Advisors added most to Seagen Inc. Common Stock in Q2 2015, an estimated $82.3M increase.
  • Baker Bros. Advisors's biggest Q2 2015 reduction was ANACOR PHARMACEUTICALS INC COM, cutting an estimated $38M.
  • Baker Bros. Advisors fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.31B.
  • Baker Bros. Advisors's ten largest holdings make up 75% of its $11.4B portfolio in Q2 2015.
  • Baker Bros. Advisors opened 10 new positions and closed 12 in Q2 2015.
  • Baker Bros. Advisors's portfolio value fell 5.2% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.